Literature DB >> 28917543

Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs.

Vivian A Fonseca1, Dragana Lovre2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28917543      PMCID： PMC5964603          DOI： 10.1016/S2213-8587(17)30320-0

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  13 in total

1.  Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.

Authors:  A Toprani; V Fonseca
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

Review 2.  REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES.

Authors:  Daniel Einhorn; Vivian Fonseca
Journal:  Endocr Pract       Date:  2016-08-19       Impact factor: 3.443

3.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Authors:  Olga Vaccaro; Maria Masulli; Antonio Nicolucci; Enzo Bonora; Stefano Del Prato; Aldo P Maggioni; Angela A Rivellese; Sebastiano Squatrito; Carlo B Giorda; Giorgio Sesti; Paolo Mocarelli; Giuseppe Lucisano; Michele Sacco; Stefano Signorini; Fabrizio Cappellini; Gabriele Perriello; Anna Carla Babini; Annunziata Lapolla; Giovanna Gregori; Carla Giordano; Laura Corsi; Raffaella Buzzetti; Gennaro Clemente; Graziano Di Cianni; Rossella Iannarelli; Renzo Cordera; Olga La Macchia; Chiara Zamboni; Cristiana Scaranna; Massimo Boemi; Ciro Iovine; Davide Lauro; Sergio Leotta; Elisabetta Dall'Aglio; Emanuela Cannarsa; Laura Tonutti; Giuseppe Pugliese; Antonio C Bossi; Roberto Anichini; Francesco Dotta; Antonino Di Benedetto; Giuseppe Citro; Daniela Antenucci; Lucia Ricci; Francesco Giorgino; Costanza Santini; Agostino Gnasso; Salvatore De Cosmo; Donatella Zavaroni; Monica Vedovato; Agostino Consoli; Maria Calabrese; Paolo di Bartolo; Paolo Fornengo; Gabriele Riccardi
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-13       Impact factor: 32.069

4.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

Authors:  James D Lewis; Laurel A Habel; Charles P Quesenberry; Brian L Strom; Tiffany Peng; Monique M Hedderson; Samantha F Ehrlich; Ronac Mamtani; Warren Bilker; David J Vaughn; Lisa Nessel; Stephen K Van Den Eeden; Assiamira Ferrara
Journal:  JAMA       Date:  2015-07-21       Impact factor: 56.272

7.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

8.  Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).

Authors:  Nikolaus Marx; Julio Rosenstock; Steven E Kahn; Bernard Zinman; John J Kastelein; John M Lachin; Mark A Espeland; Erich Bluhmki; Michaela Mattheus; Bart Ryckaert; Sanjay Patel; Odd Erik Johansen; Hans-Juergen Woerle
Journal:  Diab Vasc Dis Res       Date:  2015-03-15       Impact factor: 3.291

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

Authors:  David M Nathan; John B Buse; Steven E Kahn; Heidi Krause-Steinrauf; Mary E Larkin; Myrlene Staten; Deborah Wexler; John M Lachin
Journal:  Diabetes Care       Date:  2013-05-20       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.